Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis

American Journal of Nephrology

Volumn 34, Issue 2, 2011, Pages 175-180

  Roccatello, Dario ^a,b   Sciascia, Savino ^a   Rossi, Daniela ^a   Alpa, Mirella ^a   Naretto, Carla ^a   Russo, Alessandra ^a   Menegatti, Elisa ^a   Baldovino, Simone ^a  

^a Centro Multidisciplinare di Immunopatologia e Documentazione su Malattie Rare (CMID)   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Churg Strauss syndrome; Idiopathic systemic microscopic polyangiitis; Rituximab; Systemic vasculitis; Wegener's granulomatosis

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB;

ADD ON THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; COUGHING; CREATININE BLOOD LEVEL; DRUG FEVER; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; MAINTENANCE DRUG DOSE; MALAISE; MALE; MICROSCOPIC POLYANGIITIS; PANCYTOPENIA; PARESTHESIA; PRIORITY JOURNAL; PROTEINURIA; REFRACTORY PERIOD; RHINOSINUSITIS; WEAKNESS; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULITIS;

EID: 79960264951     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000329535     Document Type: Article

References (24)

1. Eisenberg R, Looney RJ: The therapeutic potential of anti-CD20 'what do B-cells do?'Clin Immunol 2005; 117: 207-213.
2. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-1587.
3. Cheifetz A, Mayer L: Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005; 72: 250-256.
4. Martin F, Chan AC: B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-496.
5. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220.
6. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
7. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, Mazzucco G, Sena LM: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-3061.
8. Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, Francica S, Cavallo R, Alpa M, Napoli F, Sena LM: Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008; 34: 111-117.
9. Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V: Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011 (Epub ahead of print).
10. Cavallo R, Roccatello D, Menegatti E, Naretto C, Napoli F, Baldovino S: Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009; 256: 1076-1082.
11. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA: Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-1832.
12. Mohammad AJ, Bakoush O, Sturfelt G, Segelmark M: The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index. Scand J Rheumatol 2009; 38: 268-275.
13. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
14. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361.
15. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-2469.
16. Carruthers D, Bacon P: Activity, damage and outcome in systemic vasculitis. Best Pract Res Clin Rheumatol 2001; 15: 225-238
17. Keogh KA, Ytterberg SR, Fervenza FC, Carlon KA, Schroeder DR, Specks U: Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-187.
18. Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-548.
19. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X: Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-920.
20. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G: Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 2005; 34: 229-232.
21. Aries PM, Hellmich B, Voswinkel J, Both M, Nölle B, Holl-Ulrich K, Lamprecht P, Gross WL: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-858.
22. Bosch X, Guilabert A, Espinosa G, Mirapeix E: Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: Challenging the therapeutic status quo? Trends Immunol 2008; 29: 280-289.
23. Mitchison NA: T-cell-B-cell cooperation. Nat Rev Immunol 2004; 4: 308-312.
24. Lamprecht P, Till A, Steinmann J, Aries PM, Gross WL: Current state of biologicals in the management of systemic vasculitis. Ann N Y Acad Sci 2007; 1110: 261-270